MEDICURE INC

Medicure Inc. is a pharmaceutical company that acquired the U.S. rights to its first commercial product, AGGRASTAT Injection (tirofiban hydrochloride), in August 2006 for US$19.0 million. This product is sold in the United States and its territories, including Puerto Rico, the Virgin Islands, and Guam. In September 2007, the company secured US$25 million through a debt financing agreement with Birmingham Associates Ltd., an affiliate of Elliott Associates, L.P., by monetizing a percentage of its current and potential future commercial revenues. This debt was settled in July 2011, which included a royalty agreement payable to Birmingham based on future commercial AGGRASTAT sales until 2023. The royalty structure is four percent on the first $2.0 million of quarterly AGGRASTAT sales, six percent on sales between $2.0 million and $4.0 million, and eight percent on sales exceeding $4.0 million, payable within 60 days of the quarter's end. In February 2008, the company's pivotal Phase III MEND-CABG II clinical trials with MC-1 did not meet the primary endpoint, leading to a restructuring plan in March 2008 that reduced its workforce by approximately 50 employees and full-time consultants to conserve capital. On July 18, 2011, Medicure Inc. borrowed $5,000,000 from the Government of Manitoba under the Manitoba Industrial Opportunities Program to help settle its debt to Birmingham. The company's registered and head office is located at 2-1250 Waverley Street, Winnipeg, Manitoba, Canada, R3T 6C6.